ALSO NOTED: Gilmartin denies coverup; GeneThera debunks bankruptcy rumors; and much more...

> Former Merck chief Raymond Gilmartin insisted in court that the company had been up front about the risks associated with Vioxx. Attorney Mark Lanier, though, stressed that Gilmartin's bonuses had a lot to do with the value of Merck's stock and Vioxx. Report

> GeneThera of Wheat Ridge, CO, says that people are circulating false rumors that it is about to go bankrupt as a way to depress the company's stock price. Release

> Oscient Pharmaceuticals raised $35 million in a private placement. Report

> Orchid Cellmark has received a delisting notice from Nasdaq. Report

> Genelabs Technologies has been notified it may not meet Nasdaq's financial requirements for listing. Report

> Amgen laid off 98 workers at a manufacturing site in Fremont, CA, as it began to integrate the newly acquired Abgenix into its operations. Report

> Dr. Reddy's has received FDA approval for Amlodipine to treat high blood pressure and chest pain. Report

And Finally… U.S. officials rejected a new Swedish study that has found a link between cell phones and brain tumors. Report